S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Fund/Baker Bros Advisors/Q2 2026

Baker Bros Advisors

Periodo: Q2 2026 · Depositato: 2026-08-14
Vedi su SEC EDGAR
AUM
$19.96B
Valore totale del portafoglio
Posizioni
84
Titoli dichiarati
Prima Posizione
INCY
17.5% $3.49B
Var. Trimestrali
+8 / -8
nuovi · usciti
⚠️Informativa sui Depositi 13F

I dati AUM mostrati sono calcolati sommando il valore di mercato dichiarato di tutte le posizioni nei depositi SEC 13F-HR — non rappresentano il patrimonio effettivo gestito dal fondo.

  • Escluse liquidità, obbligazioni, private equity, posizioni corte e azioni estere non soggette all'obbligo di dichiarazione.
  • Per le opzioni PUT e CALL, il Valore dichiarato è il valore nozionale delle azioni sottostanti — non il premio pagato. Ciò sovrastima significativamente il capitale effettivamente a rischio.
  • Il patrimonio reale del fondo è tipicamente superiore e include strategie, strumenti e posizioni che non compaiono mai in un 13F.
  • I depositi 13F riguardano i gestori istituzionali con ≥$100M in titoli 13F. Le posizioni riflettono le partecipazioni a fine trimestre, divulgate entro 45 giorni dalla fine del periodo.

Dati provenienti da SEC EDGAR. Questo tracker è a scopo puramente informativo e non costituisce consulenza finanziaria.

Partecipazioni in Portafoglio

Prime 30 posizioni

⚠️ Performance % calcolata dalla data di deposito ( 2026-08-14) si riferisce al titolo sottostante — non al P&L del derivato.
TickerEmittenteNozionalePortafoglio %Al DepositoOra (Fine Giornata)Dal DepositoAllocazione
INCYIncyte Corporation$3.49B17.48%$113.36$120.16+6.0%
17.5%
ONCBeOne Medicines Ltd.$2.51B12.57%$284.97$347.48+21.9%
12.6%
RVMDRevolution Medicines, Inc.$2.14B10.74%$187.28$203.71+8.8%
10.7%
MDGLMadrigal Pharmaceuticals, Inc.$1.15B5.77%$536.95$507.56-5.5%
5.8%
ACADACADIA Pharmaceuticals Inc.$1.09B5.44%$25.30$28.24+11.6%
5.4%
KYMRKymera Therapeutics, Inc.$992.7M4.97%$114.67$117.39+2.4%
5.0%
INSMInsmed Incorporated$937.8M4.70%$106.62$123.74+16.1%
4.7%
CELCCelcuity Inc.$828.1M4.15%$104.62$92.00-12.1%
4.2%
KODKodiak Sciences Inc.$776.0M3.89%$38.96$41.35+6.1%
3.9%
RYTMRhythm Pharmaceuticals, Inc.$622.3M3.12%$111.03$115.48+4.0%
3.1%
PRAXPraxis Precision Medicines, Inc.$587.0M2.94%$334.79$366.81+9.6%
2.9%
ALKSAlkermes plc$524.6M2.63%$52.40$49.06-6.4%
2.6%
SMMTSummit Therapeutics Inc.$477.7M2.39%$14.57$13.35-8.4%
2.4%
GRALGRAIL, Inc.$275.0M1.38%$68.27$67.87-0.6%
1.4%
ABCLAbCellera Biologics Inc.$259.1M1.30%$7.85$11.38+45.0%
1.3%
IMVTImmunovant, Inc.$209.4M1.05%$38.53$41.82+8.5%
1.1%
IDYAIDEAYA Biosciences, Inc.$186.7M0.94%$37.27$36.30-2.6%
0.9%
KNSAKiniksa Pharmaceuticals International, plc$181.3M0.91%$63.95$76.75+20.0%
0.9%
ROIVRoivant Sciences Ltd.$166.9M0.84%$35.39$36.20+2.3%
0.8%
ARWRArrowhead Pharmaceuticals, Inc.$162.4M0.81%$81.51$86.64+6.3%
0.8%
IONSIonis Pharmaceuticals, Inc.$162.4M0.81%$79.29$57.24-27.8%
0.8%
EWTXEdgewise Therapeutics, Inc.$150.4M0.75%$40.63$44.17+8.7%
0.8%
REPLReplimune Group, Inc.$122.3M0.61%$11.07$14.97+35.2%
0.6%
NRIXNurix Therapeutics, Inc.$113.0M0.57%$24.26$27.05+11.5%
0.6%
STOKStoke Therapeutics, Inc.$109.2M0.55%$32.72$31.27-4.4%
0.6%
GLUEMonte Rosa Therapeutics, Inc.$105.2M0.53%$24.20$15.50-36.0%
0.5%
IMTXImmatics N.V.$96.3M0.48%$10.13$9.44-6.8%
0.5%
DNLIDenali Therapeutics Inc.$96.0M0.48%$25.72$24.40-5.1%
0.5%
CRNXCrinetics Pharmaceuticals, Inc.$88.0M0.44%$37.42$84.70+126.3%
0.4%
DNTHDianthus Therapeutics, Inc.$83.1M0.42%$97.48$115.96+19.0%
0.4%

Attività Trimestre su Trimestre

Q2 2026 vs. Q1 2026

Nuove Posizioni (8)

TickerEmittenteNozionale
SNSEFaeth Therapeutics, Inc.$32.2M
CYTKCytokinetics, Incorporated$18.0M
NTLAIntellia Therapeutics, Inc.$15.7M
Parabilis Medicines, Inc.$13.7M
AVLNAvalyn Pharma Inc.$11.5M
TNGXTango Therapeutics, Inc.$10.4M
AVTXAvalo Therapeutics, Inc.$10.2M
IMNMImmunome, Inc.$1.2M

Posizioni Chiuse (8)

TickerEmittenteNozionale
ABVXAbivax S.A.$97.5M
SYRESpyre Therapeutics, Inc.$50.4M
CNTACentessa Pharmaceuticals plc$26.6M
IMCRImmunocore Holdings plc$22.1M
CTNMContineum Therapeutics, Inc.$18.6M
ARGXargenx SE$18.4M
CMPSCOMPASS Pathways plc$13.0M
PHVSPharvaris N.V.$10.6M

Aumentate (8)

TickerEmittenteNozionaleVar. AzioniDal Deposito
VSTMVerastem, Inc.$6.5M+327.4%
RLAYRelay Therapeutics, Inc.$41.4M+143.7%
RCUSArcus Biosciences, Inc.$17.1M+103.3%
CLDXCelldex Therapeutics, Inc.$22.9M+77.7%
IDYAIDEAYA Biosciences, Inc.$55.2M+26.9%-2.6%
VRDNViridian Therapeutics, Inc.$5.2M+20.9%
RVMDRevolution Medicines, Inc.$1.21B+19.8%+8.8%
INSMInsmed Incorporated$-275.7M+18.5%+16.1%

Ridotte (7)

TickerEmittenteNozionaleVar. AzioniDal Deposito
EWTXEdgewise Therapeutics, Inc.$-56.7M-43.7%+8.7%
CERSCerus Corporation$0.5M-36.1%
JBIOJade Biosciences, Inc.$4.3M-25.0%
IMTXImmatics N.V.$-11.1M-12.9%-6.8%
SMMTSummit Therapeutics Inc.$-212.3M-9.9%-8.4%
ROIVRoivant Sciences Ltd.$32.1M-3.1%+2.3%
IMVTImmunovant, Inc.$73.8M-0.4%+8.5%
Torna agli Hedge Fund